Skip to content

Prophylactic Subcutaneous Drainage After Gynecologic Oncology Midline Laparotomy

Effect of Prophylactic Subcutaneous Drainage on Wound Complications in Patients With Thick Subcutaneous Tissue Undergoing Midline Laparotomy for Gynecologic Oncology Surgery: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07735962
Acronym
SCDRAIN-GO
Enrollment
334
Registered
2026-07-30
Start date
2026-07-20
Completion date
2028-03-01
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic Cancers, Surgical Site Infection (SSI), Wound Complication

Keywords

subcutaneous drain, gynecologic oncology, midline laparotomy, wound complication, surgical site infection, subcutaneous tissue thickness, randomized controlled trial

Brief summary

The goal of this clinical trial is to learn whether placing a small drain under the skin can help prevent wound problems after gynecologic oncology surgery in adult women with a thick layer of tissue under the skin. The main question it aims to answer is: Does a small drain placed under the skin lower the number of wound complications within 30 days after surgery? Researchers will compare two groups: Participants in one group will have a small closed-suction drain placed under the skin before the skin is closed. Participants in the other group will not have a drain placed under the skin. All participants will have midline abdominal surgery. During surgery, the surgeon will measure the thickness of the tissue under the skin. Participants with a thickness of 2.5 cm or more will be randomly assigned to one of the two groups. In both groups, the tissue under the skin will be closed in a standard way using separate 2/0 Vicryl stitches. Participants in the drain group will have the drain removed when the amount of fluid collected in 24 hours is less than 30 mL, unless the surgeon decides that earlier or later removal is needed. Participants will be followed for 30 days after surgery to check for wound problems such as infection, wound separation, fluid collection, blood collection, or the need for extra wound care or another procedure.

Detailed description

Wound complications after gynecologic oncology surgery are clinically important because they may increase postoperative morbidity, delay recovery, prolong hospital stay, and postpone planned adjuvant treatment. Increased subcutaneous tissue thickness is a recognized surgical risk factor for wound-related problems after abdominal surgery. However, the benefit of routinely placing a prophylactic drain in the subcutaneous tissue remains uncertain, and practice varies among surgeons. This study will evaluate a standardized approach to prophylactic subcutaneous drainage in participants undergoing gynecologic oncology surgery through a midline laparotomy. The study is designed as a single-center, prospective, randomized, open-label, parallel-group clinical trial. Because the intervention is a surgical procedure that is visible to the operating team and to postoperative care providers, masking will not be used. Written informed consent will be obtained before surgery from potentially eligible participants. The final eligibility for randomization will be confirmed during surgery by measuring the subcutaneous tissue thickness with a sterile ruler at the thickest part of the incision. Participants who meet the intraoperative thickness requirement will be assigned to one of the study groups using a pre-generated randomization sequence and sequentially numbered, opaque, sealed envelopes. The study compares two standard surgical approaches used in routine clinical practice: placement of a closed-suction drain in the subcutaneous tissue versus no subcutaneous drain. No investigational drug, biological product, or experimental medical device will be used. In both groups, subcutaneous tissue approximation will be standardized with interrupted 2/0 Vicryl sutures. In the drainage group, the subcutaneous drain will be managed according to a predefined removal criterion based on the 24-hour drainage volume, unless clinical circumstances require a different decision. Postoperative care will otherwise follow the usual clinical practice of the gynecologic oncology surgery service. Wound-related findings and postoperative clinical data will be collected during hospitalization, at discharge, and during the postoperative follow-up period. Hospital records, outpatient assessments, readmission records, and telephone follow-up may be used to complete follow-up information when needed. The primary analysis will follow the intention-to-treat principle, with participants analyzed according to their randomized group. A supportive per-protocol analysis will also be performed to assess the effect of protocol adherence. The main treatment effect will be expressed using absolute risk difference with 95% confidence intervals, with relative effect estimates reported as additional measures. The results are expected to clarify whether routine prophylactic subcutaneous drainage provides clinically meaningful benefit in patients with thick subcutaneous tissue undergoing gynecologic oncology midline laparotomy. Prespecified exploratory analyses will examine the association between baseline and intraoperative variables (body mass index, diabetes mellitus, preoperative hemoglobin, preoperative serum albumin, operative duration, bowel intervention, and subcutaneous tissue thickness) and 30-day composite wound complication using multivariable logistic regression. These analyses are exploratory and are not registered as outcome measures.

Interventions

PROCEDUREProphylactic subcutaneous closed-suction drainage

Placement of a closed-suction drain in the subcutaneous tissue before skin closure in patients with intraoperative subcutaneous tissue thickness of 2.5 cm or greater.

PROCEDUREStandard closure without subcutaneous drainage

Standardized subcutaneous tissue approximation and skin closure without placement of a prophylactic subcutaneous drain.

Sponsors

Mahmut Yassa
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

No masking will be used. The intervention is a surgical procedure, and the presence or absence of a subcutaneous drain is visible to the surgical team, postoperative care providers, and participants.

Intervention model description

Participants who provide written informed consent before surgery will undergo intraoperative measurement of subcutaneous tissue thickness. Participants with subcutaneous tissue thickness of 2.5 cm or greater will be randomized in a 1:1 ratio to one of two parallel groups: prophylactic subcutaneous drainage or no subcutaneous drainage. Randomization will be performed using a pre-generated block randomization sequence with sequentially numbered, opaque, sealed envelopes.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female participants aged 18 years or older * Undergoing midline laparotomy for gynecologic oncology surgery * Intraoperative subcutaneous tissue thickness of 2.5 cm or greater, measured at the thickest part of the incision * Able and willing to provide written informed consent before surgery

Exclusion criteria

* Emergency surgery * Active infection before surgery * Severe immunosuppression * Refusal to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Composite wound complication within 30 postoperative daysUp to 30 days after surgeryThe primary outcome is the incidence of composite wound complication within 30 postoperative days. Composite wound complication is defined as the occurrence of at least one of the following: surgical site infection, wound dehiscence, clinically significant subcutaneous seroma, clinically significant subcutaneous hematoma, or wound-related intervention. Clinically significant subcutaneous seroma or hematoma is defined as a seroma or hematoma requiring any additional wound care beyond routine postoperative care, unscheduled clinical assessment, imaging, antibiotic treatment, aspiration, drainage, readmission, or surgical intervention. Wound-related intervention is defined as any wound-directed procedure (aspiration, drainage, re-suturing, surgical revision, or operative wound debridement) performed because of a postoperative wound complication, in either an inpatient or outpatient setting.

Secondary

MeasureTime frameDescription
Surgical site infection within 30 postoperative daysUp to 30 days after surgeryIncidence of surgical site infection within 30 postoperative days, including superficial or deep incisional surgical site infection as clinically diagnosed and recorded during postoperative follow-up.
Wound dehiscence within 30 postoperative daysUp to 30 days after surgeryIncidence of wound dehiscence within 30 postoperative days, including superficial or deep wound separation documented during postoperative follow-up.
Clinically significant subcutaneous seroma within 30 postoperative daysUp to 30 days after surgeryIncidence of clinically significant subcutaneous seroma within 30 postoperative days. Clinically significant seroma is defined as a seroma requiring additional wound care beyond routine postoperative care, unscheduled clinical assessment, imaging, antibiotic treatment, aspiration, drainage, readmission, or surgical intervention.
Clinically significant subcutaneous hematoma within 30 postoperative daysUp to 30 days after surgeryIncidence of clinically significant subcutaneous hematoma within 30 postoperative days. Clinically significant hematoma is defined as a hematoma requiring additional wound care beyond routine postoperative care, unscheduled clinical assessment, imaging, antibiotic treatment, aspiration, drainage, readmission, or surgical intervention.
Wound-related intervention within 30 postoperative daysUp to 30 days after surgeryIncidence of wound-related intervention within 30 postoperative days. Wound-related intervention is defined as any wound-directed procedure performed because of a postoperative wound complication, including aspiration, drainage, re-suturing, surgical revision, or operative wound debridement, regardless of whether the procedure is performed in an inpatient or outpatient setting.
Wound-related readmission within 30 postoperative daysUp to 30 days after surgeryIncidence of hospital readmission within 30 postoperative days due to a wound-related complication.
Postoperative length of hospital stayFrom the date of surgery to hospital discharge, assessed up to 30 days after surgeryLength of postoperative hospital stay, defined as the number of days from surgery to hospital discharge.
Subcutaneous tissue thickness in participants with and without 30-day composite wound complicationUp to 30 days after surgerySubcutaneous tissue thickness, measured in centimeters intraoperatively with a sterile ruler at the thickest part of the midline incision, reported separately for participants with and without composite wound complication within 30 postoperative days.

Countries

Turkey (Türkiye)

Contacts

CONTACTMAHMUT yassa, MD
mahmut_yassa@hotmail.com+905396635484
CONTACTBora Taşpınar, MD
borataspinar@gmail.com+905053946331
PRINCIPAL_INVESTIGATORMAHMUT YASSA, MD

Başakşehir Çam & Sakura City Hospital

STUDY_DIRECTORBora Taşpınar, MD

Başakşehir Çam & Sakura City Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026